Gilead Sciences's Options: A Look at What the Big Money is Thinking

Investors with a lot of money to spend have taken a bullish stance on Gilead Sciences GILD.

And retail traders should know.

We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.

Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with GILD, it often means somebody knows something is about to happen.

So how do we know what these investors just did?

Today, Benzinga's options scanner spotted 8 uncommon options trades for Gilead Sciences.

This isn't normal.

The overall sentiment of these big-money traders is split between 50% bullish and 37%, bearish.

Out of all of the special options we uncovered, 3 are puts, for a total amount of $233,330, and 5 are calls, for a total amount of $272,215.

What's The Price Target?

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $70.0 and $125.0 for Gilead Sciences, spanning the last three months.

Insights into Volume & Open Interest

In today's trading context, the average open interest for options of Gilead Sciences stands at 694.14, with a total volume reaching 1,574.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Gilead Sciences, situated within the strike price corridor from $70.0 to $125.0, throughout the last 30 days.

Gilead Sciences 30-Day Option Volume & Interest Snapshot

Largest Options Trades Observed:

About Gilead Sciences

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Gilead Sciences's Current Market Status

• With a volume of 2,838,967, the price of GILD is up 1.24% at $118.87.
• RSI indicators hint that the underlying stock may be overbought.
• Next earnings are expected to be released in 45 days.

Professional Analyst Ratings for Gilead Sciences

Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $111.0.

Unusual Options Activity Detected: Smart Money on the Move

Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access. * Showing optimism, an analyst from Deutsche Bank upgrades its rating to Buy with a revised price target of $120. * An analyst from Wells Fargo persists with their Overweight rating on Gilead Sciences, maintaining a target price of $120. * An analyst from RBC Capital has decided to maintain their Sector Perform rating on Gilead Sciences, which currently sits at a price target of $90. * Consistent in their evaluation, an analyst from BMO Capital keeps a Outperform rating on Gilead Sciences with a target price of $115. * An analyst from Piper Sandler has decided to maintain their Overweight rating on Gilead Sciences, which currently sits at a price target of $110.

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Gilead Sciences with Benzinga Pro for real-time alerts.